ArticleOrphanet journal of rare diseases2025
Pediatric pulmonary hemorrhage observed in non-vascular and vascular Ehlers-Danlos syndrome.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multigene panel analysis of connective tissue and vascular genes in patients with a bleeding disorder of unknown cause or a cerebrovascular event.Research and practice in thrombosis and haemostasis · 2026Article
- Pulmonary hemorrhage as an early clue: an integrated clinical-imaging-genetic diagnostic insight for vascular Ehlers-Danlos syndrome.Orphanet journal of rare diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEhlers-Danlos syndrome (EDS) is a heterogeneous group of heritable connective tissue disorders with varying features depending on the EDS subtype. EDS is associated with various respiratory manifestations. Pulmonary hemorrhage has been previously reported in vascular EDS (vEDS); however, this manifestation remains not particularly well-defined in other subtypes of EDS. This study extends the clinical understanding of EDS, particularly non-vascular EDS, and expands etiological spectrum of pulmonary hemorrhage in children.
methodsWe retrospectively analyzed the records of patients diagnosed with EDS between January 2020 and November 2024 at our institute. All clinical data was extracted from the electronic medical records, including clinical presentation, physical examination, family history, and chest computed tomography scans. EDS was confirmed based on clinical manifestations, pathological biopsies, immunohistochemistry, immunofluorescence staining, and genetic testing.
resultsOur study identified eight patients with EDS who presented with pulmonary hemorrhage. Among these eight patients, nine gene mutations were identified, including four in COL3A1, two in COL1A1, one in COL1A2, one in TNXB, and one in COL4A2. We identified the mutations: IVS44 + 1G→A and c.1550 C > T (p. Pro517Leu) of COL3A1 gene as two novel mutations associated with vEDS. And we added pathogenic evidences of the mutations c.1550 C > T (p. Pro517Leu) and c.3133G > A (p. Ala1045Thr) in COL3A1 gene.
conclusionsTwo novel and two pathogenic mutations in COL3A1 gene associated with vEDS, COL1A1, COL1A2, TNXB gene mutations of non-vascular types underlying EDS and COL4A2 gene associated with collagen synthesis were found in patients presenting with pulmonary hemorrhage. These findings would enhance clinical recognition of EDS and provide a sound basis to recommend that children with pulmonary hemorrhage be routinely examined for joint and skin hyperextension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.